BACKGROUND: Anti-citrullinated protein antibodies (ACPA) are specifically and frequently detected in sera of patients with rheumatoid arthritis (RA). Citrullinated fibrin or fibrinogen is a candidate autoantigen of such antibodies. OBJECTIVE: To investigate the presence of citrullinated fibrinogen (cFBG) in the plasma or synovial fluid of patients with RA and control patients, and to determine cFBG levels and their relationship with serum markers for RA if it is present. METHODS: A sandwich enzyme linked immunosorbent assay (ELISA) to measure cFBG was established using monoclonal antibodies cF16.1 and cF252.1, generated by immunising mice with R16Cit and R252Cit, the fibrinogen Aalpha chain derived sequences with citrulline at position 16 and 252, respectively, and the presence of cFBG was further investigated with immunoprecipitation-western blotting. RESULTS: Positive signals were detected in 11/15 RA synovial fluids (RASFs), but not in osteoarthritis synovial fluids or RA plasma with sandwich ELISA for cFBG using cF16.1 and an anti-modified citrulline (AMC) antibody. The presence of cFBG in RASFs was confirmed by immunoprecipitation-western blotting. Furthermore, most RA sera strongly reacted against R16Cit. No relationship was seen between RASF cFBG levels and C reactive protein or anti-cyclic citrullinated peptide antibody levels of the paired sera. CONCLUSION: cFBG is detected as a soluble citrullinated autoantigen in RASFs and may therefore be a genuine candidate antigen for ACPA in patients with RA.
BACKGROUND: Anti-citrullinated protein antibodies (ACPA) are specifically and frequently detected in sera of patients with rheumatoid arthritis (RA). Citrullinated fibrin or fibrinogen is a candidate autoantigen of such antibodies. OBJECTIVE: To investigate the presence of citrullinated fibrinogen (cFBG) in the plasma or synovial fluid of patients with RA and control patients, and to determine cFBG levels and their relationship with serum markers for RA if it is present. METHODS: A sandwich enzyme linked immunosorbent assay (ELISA) to measure cFBG was established using monoclonal antibodies cF16.1 and cF252.1, generated by immunising mice with R16Cit and R252Cit, the fibrinogenAalpha chain derived sequences with citrulline at position 16 and 252, respectively, and the presence of cFBG was further investigated with immunoprecipitation-western blotting. RESULTS: Positive signals were detected in 11/15 RA synovial fluids (RASFs), but not in osteoarthritis synovial fluids or RA plasma with sandwich ELISA for cFBG using cF16.1 and an anti-modified citrulline (AMC) antibody. The presence of cFBG in RASFs was confirmed by immunoprecipitation-western blotting. Furthermore, most RA sera strongly reacted against R16Cit. No relationship was seen between RASF cFBG levels and C reactive protein or anti-cyclic citrullinated peptide antibody levels of the paired sera. CONCLUSION: cFBG is detected as a soluble citrullinated autoantigen in RASFs and may therefore be a genuine candidate antigen for ACPA in patients with RA.
Authors: O Sánchez-Pernaute; R Largo; E Calvo; M A Alvarez-Soria; J Egido; G Herrero-Beaumont Journal: Ann Rheum Dis Date: 2003-12 Impact factor: 19.103
Authors: C Masson-Bessière; M Sebbag; E Girbal-Neuhauser; L Nogueira; C Vincent; T Senshu; G Serre Journal: J Immunol Date: 2001-03-15 Impact factor: 5.422
Authors: A K So; P-A Varisco; B Kemkes-Matthes; C Herkenne-Morard; V Chobaz-Péclat; J-C Gerster; N Busso Journal: J Thromb Haemost Date: 2003-12 Impact factor: 5.824
Authors: E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij Journal: Ann Rheum Dis Date: 2004-04 Impact factor: 19.103
Authors: K Suzuki; T Sawada; A Murakami; T Matsui; S Tohma; K Nakazono; M Takemura; Y Takasaki; T Mimori; K Yamamoto Journal: Scand J Rheumatol Date: 2003 Impact factor: 3.641
Authors: Altan Ercan; Jing Cui; Dereck E W Chatterton; Kevin D Deane; Melissa M Hazen; William Brintnell; Colin I O'Donnell; Lezlie A Derber; Michael E Weinblatt; Nancy A Shadick; David A Bell; Ewa Cairns; Daniel H Solomon; V Michael Holers; Pauline M Rudd; David M Lee Journal: Arthritis Rheum Date: 2010-08
Authors: Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava Journal: Clin Rev Allergy Immunol Date: 2014-08 Impact factor: 8.667
Authors: Katleen Van Steendam; Kelly Tilleman; Marlies De Ceuleneer; Filip De Keyser; Dirk Elewaut; Dieter Deforce Journal: Arthritis Res Ther Date: 2010-07-07 Impact factor: 5.156
Authors: Raimon Sanmartí; Eduard Graell; Maria L Perez; Guadalupe Ercilla; Odette Viñas; Jose A Gómez-Puerta; Jordi Gratacós; Alejandro Balsa; Maria J Gómara; Marta Larrosa; Juan D Cañete; Isabel Haro Journal: Arthritis Res Ther Date: 2009-09-02 Impact factor: 5.156